Subhdeep Virk, MBBS: Emerging Therapies for Treatment Resistant Depression

Article

Virk will chair a discussion on depression treatments on March 3.

Solving treatment-resistant depression has proven costly and challenging.

With many patients not responding to first, second, or third options of antidepressants, it is crucial to overcome this resistance barrier.

However, new treatments may soon emerge that has clinicians and investigators hopeful they will soon be able to overcome this long-standing challenge.

In an interview with HCPLive®, Subhdeep Virk, MBBS, an associate professor of clinical psychiatry and director of the Treatment Resistant Depression Program at Ohio State University’s Wexner Medical Department of Psychiatry, talked about the emergence of new therapies for depression and how there is hope on the horizon in treating this patient population

Virk will be chairing a discussion on treatment-resistant depression on March 3 as part of HCPLive’s State of the Science program called Institutional Perspectives in Psychiatry: Addressing Challenges in Depression Treatment.

The discussion will look at newer treatment options and why there is a need for novel, evidence-based treatments for depression.

“There are a lot of newer treatments for depression,” Virk said. “What my focus will be on is ketamine and esketamine. Those are the 2 treatments that have been more recently added to the group of treatments for treatment-resistant depression.”

Recent Videos
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
© 2024 MJH Life Sciences

All rights reserved.